Home/Pipeline/PROGRAM-1

PROGRAM-1

solid tumor, cancer associated fibroblast

Pre-ClinicalActive

Key Facts

Indication
solid tumor, cancer associated fibroblast
Phase
Pre-Clinical
Status
Active
Company

About Optieum Biotechnologies

A Japanese biotech developing optimized CAR-T therapies for solid tumors and autoimmune disorders using its proprietary Eumbody discovery platform.

View full company profile

Therapeutic Areas